If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-05. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== Production === Valve developed several VR prototypes, with three projects under development by 2017. They found the portal systems of their puzzle series Portal were disorienting in VR, but that the Half-Life systems were a natural fit. Walker said that Half-Life 3 had been a "terrifyingly daunting prospect", and the team saw VR as a way to return to the series. Additionally, they anticipated that fans would react negatively if Half-Life 3 were a VR-only game and felt a prequel carried less weight. Valve built prototypes using Half-Life 2 assets and narrowed the gameplay systems to those that best fit VR. VR affected almost every aspect of the design, including combat, level design and pacing. For example, shooting in VR, which requires the player to physically position their hand in space, is a different experience from aiming with traditional mouse-and-keyboard controls. Mike Morasky, the composer for Portal 2 and Team Fortress 2, wrote the score in consultation with Kelly Bailey, the composer for previous Half-Life games. He cited industrial music by acts such as Nine Inch Nails, the Prodigy and Skinny Puppy as inspiration. Half-Life: Alyx entered development around February 2016 and entered full production later that year. The team, comprising around 80 people, was the largest in Valve's history, and included Campo Santo, a studio Valve acquired in 2018. As Valve had repeatedly failed to see projects through, some staff were reluctant to join and many were skeptical that VR was the right direction.
To perform a selective separation, the distribution ratio of the solute to be extracted must be greater than one, whereas that belonging to the solutes which remain in the aqueous feed must be lower than one. This always yields a separation factor SF > 1. Generally, the effects of acidity and temperature on distribution ratios and the separation factor are investigated because the main species with actinides and lanthanides could be prone to decomplexation upon increasing acidity due to protonation of the ligand or due to increasing temperature. The thermodynamic effects are usually investigated by performing extraction tests at increasing temperature. Furthermore, thermodynamics studies can assess the several alkyl chains of a ligand on its complexation properties towards minor actinides than lanthanides. The extraction processes are based on the complexation of metal ions with lipophilic or hydrophilic ligands. The extracting agent forms a coordination complex with the metal ion as a product of a Lewis acid-base reaction. Ligands are named bases (donors) and contain at least one electron lone pair to donate to metal ions named acids (acceptors). Metal cations in the aqueous feed raffinate are generally solvated by coordinating water molecules through the donor oxygen atoms to form aquo ions
Margaret Belle (Oakley) Dayhoff (March 11, 1925 – February 5, 1983) was an American biophysicist and a pioneer in the field of bioinformatics. Dayhoff was a professor at Georgetown University Medical Center and a noted research biochemist at the National Biomedical Research Foundation, where she pioneered the application of mathematics and computational methods to the field of biochemistry. She dedicated her career to applying the evolving computational technologies to support advances in biology and medicine, most notably the creation of protein and nucleic acid databases and tools to interrogate the databases. She originated one of the first substitution matrices, point accepted mutations (PAM). The one-letter code used for amino acids was developed by her, reflecting an attempt to reduce the size of the data files used to describe amino acid sequences in an era of punch-card computing. Her PhD degree was from Columbia University in the department of chemistry, where she devised computational methods to calculate molecular resonance energies of several organic compounds. She did postdoctoral studies at the Rockefeller Institute (now Rockefeller University) and the University of Maryland, and joined the newly established National Biomedical Research Foundation in 1959. She was the first woman to hold office in the Biophysical Society and the first person to serve as both secretary and eventually president.
=== Special populations === It is recommended that women with active tuberculosis who are pregnant or breastfeeding take isoniazid. Preventive therapy should be delayed until after giving birth. Nursing mothers excrete a relatively low and non-toxic concentration of INH in breast milk, and their babies are at low risk for side effects. Both pregnant women and infants being breastfed by mothers taking INH should take vitamin B6 in its pyridoxine form to minimize the risk of peripheral nerve damage. Vitamin B6 is used to prevent isoniazid-induced B6 deficiency and neuropathy in people with a risk factor, such as pregnancy, lactation, HIV infection, alcoholism, diabetes, kidney failure, or malnutrition. People with liver dysfunction are at a higher risk for hepatitis caused by INH, and may need a lower dose. Levels of liver enzymes in the bloodstream should be frequently checked in daily alcohol drinkers, pregnant women, IV drug users, people over 35, and those who have chronic liver disease, severe kidney dysfunction, peripheral neuropathy, or HIV infection since they are more likely to develop hepatitis from INH.
In May 2007, Unilever became the first company to commit to sourcing all tea in a sustainable manner. Working with the Rainforest Alliance, an international environmental NGO, Unilever, announced all Lipton Yellow Label tea bags sold in Western Europe would be certified by 2010 and all Lipton tea bags sold globally by 2015. Lipton's own tea estates were among the first to be certified. Lipton tea bearing the Rainforest Alliance seal appeared on Western European markets in 2008 and started appearing in North America in 2009. On 6 May 2009, Lipton received a Corporate Green Globe Award for its work with the Rainforest Alliance. In 2011, PETA criticized Unilever for conducting and funding experiments on rabbits, pigs and other animals in an attempt to make human health claims about the tea's ingredients. According to the animal rights organization, Unilever decided to end the practice after receiving more than 40,000 appeals from PETA supporters and days before PETA made plans to launch its "Lipton CruelTEA" campaign. Unilever no longer tests their products on animals unless required to by governments as part of their regulatory requirements. Unilever reached an agreement in November 2021 to sell the majority of its tea business to private equity firm CVC Capital Partners for €4.5 billion. This included the Lipton brand except where Unilever retained its use for tea in India, Nepal, and Indonesia, for ready to drink teas globally, and for soup mixes in North America. The sale was completed in July 2022, with the new company named ‘Lipton Teas and Infusions’.
Sources: en.wikipedia.org
In May 2010, In-N-Out announced plans to open new spots into Texas, specifically within the Dallas–Fort Worth area with the first In-N-Out opening in Frisco and Allen on May 11, 2011. The chain opened its first location in Austin in December 2013. There are 18 restaurant locations in the Dallas–Fort Worth area, and four in the Austin area. These new locations in Texas required the company to build a new patty production facility and distribution center in the state, according to company vice president Carl Van Fleet. In March 2014, the company confirmed its first location in San Antonio. The fall of 2014 saw the restaurant open its 22nd Texas location in Killeen. On November 20, 2014, In-N-Out opened its first location in San Antonio followed by its first location in Waco in November 2015. In January 2017, In-N-Out announced plans to expand into Houston with multiple sites planned in the area, the first being in Stafford. In January 2015, In-N-Out opened its 300th restaurant, which was located in Anaheim, California. At the time of the opening, the company had generated $558 million in annual sales and employed nearly 18,000 in California, Nevada, Utah, Texas, and Arizona. The company opened its first location in Oregon on September 9, 2015 (the same day as Harry Snyder's birthday) in Medford. It is supplied from the Lathrop, California, distribution center completed in 2006. President Lynsi Snyder stated during the opening that they will continue to open new spots. A second Oregon location was under construction in Grants Pass during September 2017.
Laminins are a family of glycoproteins of the extracellular matrix of all animals. They are major constituents of the basement membrane, namely the basal lamina (the protein network foundation for most cells and organs). Laminins are vital to biological activity, influencing cell differentiation, migration, and adhesion. Laminins are heterotrimeric protein complexes with a high molecular mass (~400 to ~900 kDa) and possess three different chains (α, β, and γ) encoded by five, four, and three paralogous genes in humans, respectively. The laminin molecules are named according to their chain composition, e.g. laminin-511 contains α5, β1, and γ1 chains. Fourteen other chain combinations have been identified in vivo. The trimeric proteins intersect, composing a cruciform structure that is able to bind to other molecules of the extracellular matrix and cell membrane. The three short arms have an affinity for binding to other laminin molecules, conducing sheet formation. The long arm is capable of binding to cells and helps anchor organized tissue cells to the basement membrane. Laminins are integral to the structural scaffolding of almost every tissue of an organism—secreted and incorporated into cell-associated extracellular matrices. These glycoproteins are imperative to the maintenance and vitality of tissue; defective laminins can cause muscles to form improperly, leading to a form of muscular dystrophy, lethal skin blistering disease (junctional epidermolysis bullosa), and/or defects of the kidney filter (nephrotic syndrome).
== History == The prothrombin time was developed by Armand J. Quick and colleagues in 1935, and a second method was published by Paul Owren, also called the "p and p" or "prothrombin and proconvertin" method. It aided in the identification of the anticoagulants dicumarol and warfarin, and was used subsequently as a measure of activity for warfarin when used therapeutically. The INR was invented in the early 1980s by Tom Kirkwood working at the UK National Institute for Biological Standards and Control (and subsequently at the UK National Institute for Medical Research) to provide a consistent way of expressing the prothrombin time ratio, which had previously suffered from a large degree of variation between centres using different reagents. The INR was coupled to Dr Kirkwood's simultaneous invention of the International Sensitivity Index (ISI), which provided the means to calibrate different batches of thromboplastins to an international standard. The INR became widely accepted worldwide, especially after endorsement by the World Health Organization.
Prince August Wilhelm married his cousin Princess Alexandra Victoria of Schleswig-Holstein-Sonderburg-Glücksburg on 22 October 1908 at the Berliner Stadtschloss. The couple had planned to take up residence in Schönhausen Palace in Berlin, but changed their mind when his father, Kaiser Wilhelm, decided to leave his son the Villa Liegnitz in the Sanssouci Park. In 1912 their only child, Prince Alexander Ferdinand of Prussia, was born. Their Potsdam residence developed into a meeting place for artists and scholars. In the First World War, August Wilhelm was made district administrator (Landrat) of the district of Ruppin; his office and residence was now Schloss Rheinsberg. His personal adjutant Hans Georg von Mackensen played an important role in his life; the two had been close friends since August Wilhelm's youth. These "pronounced homophilic tendencies" contributed to the failure of his marriage to Princess Alexandra Victoria. The couple did not divorce while August Wilhelm's father, Kaiser Wilhelm II, was Emperor, owing to his opposition to the idea.
Sulfur forms several polyatomic molecules. The best-known allotrope is octasulfur, cyclo-S8. The point group of cyclo-S8 is D4d and its dipole moment is 0 D. Octasulfur is a soft, bright-yellow solid that is odorless. It melts at 115.21 °C (239.38 °F), and boils at 444.6 °C (832.3 °F). At 95.2 °C (203.4 °F), below its melting temperature, cyclo-octasulfur begins slowly changing from α-octasulfur to the β-polymorph. The structure of the S8 ring is virtually unchanged by this phase transition, which affects the intermolecular interactions. Cooling molten sulfur freezes at 119.6 °C (247.3 °F), as it predominantly consists of the β-S8 molecules. Between its melting and boiling temperatures, octasulfur changes its allotrope again, turning from β-octasulfur to γ-sulfur, again accompanied by a lower density but increased viscosity due to the formation of polymers. At higher temperatures, the viscosity decreases as depolymerization occurs. Molten sulfur assumes a dark red color above 200 °C (392 °F). The density of sulfur is about 2 g/cm3, depending on the allotrope; all of the stable allotropes are excellent electrical insulators. The sublimation of sulfur becomes noticeable more or less between 20 °C (68 °F) and 50 °C (122 °F), and occurs readily in boiling water at 100 °C (212 °F). Sulfur is insoluble in water but soluble in carbon disulfide and, to a lesser extent, in other nonpolar organic solvents, such as benzene and toluene. Sulfur is also soluble in supercritical carbon dioxide.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.